Premas Biotech, Oramed Pharma together to develop oral COVID-19 vaccine effective after single dose
Advertisement
Gurugram Premas Biotech, a developer of novel biotherapeutic and vaccine candidates, has recently announced the development of an oral COVID-19 vaccine that has shown efficacy after a single dose, in conjunction with Oramed Pharmaceuticals Inc.
Accelerating the vaccine's path to market, Premas, Oramed and other shareholders, have formed Oravax Medical Inc. which has received exclusive licenses from Oramed and Premas to develop oral COVID-19 vaccines.
After a single dose of the Oravax COVID-19 capsule, efficacy was evident through antibody production in a pilot animal study. Oravax's vaccine promoted both systemic immunity through Immunoglobulin G (IgG), the most common antibody in blood and bodily fluids that protects against viral infections, and Immunoglobulin A (IgA) which protects the respiratory and gastrointestinal tracts against infection.
Premas' protein-based VLP (Virus Like Particle) vaccine candidate creates triple protection against the SARS CoV-2 virus Spike, Membrane, and Envelope targets. The vaccine candidate is also safe, efficacious and well-tolerated at normal to high doses, and generated high titres of neutralizing antibodies. The VLP is manufactured using Premas' proprietary D-Crypt platform, which is highly scalable and can be manufactured on large scales.
Premas Biotech Co-Founder and Managing Director Dr. Prabuddha Kundu commented, "An oral COVID-19 vaccine that harnesses and combines the true potential of the two platforms, Premas' D-Crypt technology platform with Oramed's world-leading oral protein delivery platform POD is an excellent example of a true collaboration and can rapidly advance into late-stage clinical trials. Oramed's experience and success in conducting Phase 2 and 3 oral protein trials positions our program very favorably in the race to find an effective oral COVID-19 vaccine that can be administered by anyone anywhere We are looking forward to sharing clinical data soon."
"We are very excited about our oral vaccine candidate's potential to help end the pandemic," said Nadav Kidron, CEO of Oramed. "An oral COVID-19 vaccine would eliminate several barriers to rapid, widescale distribution, enabling people to take the vaccine themselves at home. While ease of administration is critical today to accelerate inoculation rates, an oral vaccine could become even more valuable in the likely case that a COVID-19 vaccine may be required annually or biannually like the standard flu shot."
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.